Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Pavel, Marianne E, Prof, Hainsworth, John D, Prof, Baudin, Eric, MD, Peeters, Marc, Prof, Hörsch, Dieter, Prof, Winkler, Robert E, MD, Klimovsky, Judith, MD, Lebwohl, David, MD, Jehl, Valentine, MSc, Wolin, Edward M, MD, Öberg, Kjell, Prof, Van Cutsem, Eric, Prof, Yao, James C, Dr
Published in The Lancet (British edition) (10.12.2011)
Published in The Lancet (British edition) (10.12.2011)
Get full text
Journal Article
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
THOMAS, Eva S, GOMEZ, Henry L, BINGHE XU, CAMPONE, Mario, LERZO, Guillermo L, PECK, Ronald A, MUKHOPADHYAY, Pralay, VAHDAT, Linda T, ROCHE, Henri H, LI, Rubi K, CHUNG, Hyun-Cheol, FEIN, Luis E, CHAN, Valorie F, JASSEM, Jacek, PIVOT, Xavier B, KLIMOVSKY, Judith V, HURTADO DE MENDOZA, Fernando
Published in Journal of clinical oncology (20.11.2007)
Published in Journal of clinical oncology (20.11.2007)
Get full text
Journal Article
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases
Lebwohl, David, Anak, Özlem, Sahmoud, Tarek, Klimovsky, Judith, Elmroth, Ingrid, Haas, Tomas, Posluszny, Joseph, Saletan, Stephen, Berg, William
Published in Annals of the New York Academy of Sciences (01.07.2013)
Published in Annals of the New York Academy of Sciences (01.07.2013)
Get full text
Journal Article
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
THOMAS, Eva, TABERNERO, Josep, BASELGA, José, RIVERA, Edgardo, GUARNERI, Valentina, POULART, Valerie, KLIMOVSKY, Judith, LEBWOHL, David, MARTIN, Miguel, FORNIER, Monica, CONTE, Pierfranco, FUMOLEAU, Pierre, LLUCH, Ana, VAHDAT, Linda T, BUNNELL, Craig A, BURNS, Howard A, VIENS, Patrice
Published in Journal of clinical oncology (10.08.2007)
Published in Journal of clinical oncology (10.08.2007)
Get full text
Journal Article
Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study
Fazio, Nicola, Granberg, Dan, Grossman, Ashley, Saletan, Stephen, Klimovsky, Judith, Panneerselvam, Ashok, Wolin, Edward M
Published in Chest (2013)
Published in Chest (2013)
Get more information
Journal Article
Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer
Papadimitrakopoulou, Vassiliki A., Soria, Jean-Charles, Jappe, Annette, Jehl, Valentine, Klimovsky, Judith, Johnson, Bruce E.
Published in Journal of thoracic oncology (01.10.2012)
Published in Journal of thoracic oncology (01.10.2012)
Get full text
Journal Article
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single‐arm, phase 2 study
Wang, Michael, Popplewell, Leslie L., Collins, Robert H., Winter, Jane N., Goy, Andre, Kaminski, Mark S., Bartlett, Nancy L., Johnston, Patrick B., Lister, John, Fanning, Suzanne R., Tuscano, Joseph M., Beck, J. Thaddeus, Kaya, Hakan, Robeva, Anna, Fan, Jenna, Klimovsky, Judith, Cheung, Wing, Cherfi, Azzeddine, O'Connor, Owen A.
Published in British journal of haematology (01.05.2014)
Published in British journal of haematology (01.05.2014)
Get full text
Journal Article
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
Signorovitch, James, Swallow, Elyse, Kantor, Evan, Wang, Xufang, Klimovsky, Judith, Haas, Tomas, Devine, Beth, Metrakos, Peter
Published in Experimental hematology & oncology (06.12.2013)
Published in Experimental hematology & oncology (06.12.2013)
Get full text
Journal Article
Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison of randomized trials
Signorovitch, James E., Swallow, Elyse, Kantor, Evan, Wang, Xufang, Hass, Tomas, Klimovsky, Judith, Metrakos, Peter
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article
Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib
Wang, Michael, Popplewell, Leslie, Collins, Robert H., Winter, Jane N., Goy, Andre, Robeva, Anna, Pirotta, Nicoletta, Fan, Jenna, Klimovsky, Judith, O'Connor, Owen A.
Published in Blood (16.11.2012)
Published in Blood (16.11.2012)
Get full text
Journal Article
Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET)
Yao, James C., Hainsworth, John D., Wolin, Edward M., Pavel, Marianne E., Baudin, Eric, Gross, David, Ruszniewski, Philippe, Tomassetti, Paola, Panneerselvam, Ashok, Saletan, Stephen, Klimovsky, Judith
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article
Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors
Shimizu, Toshio, Yamamoto, Noboru, Yamada, Yasuhide, Fujisaka, Yasuhito, Yamada, Kazuhiko, Fujiwara, Yutaka, Takayama, Kyoko, Tokudome, Takuto, Klimovsky, Judith, Tamura, Tomohide
Published in Cancer chemotherapy and pharmacology (01.04.2008)
Published in Cancer chemotherapy and pharmacology (01.04.2008)
Get full text
Journal Article
Phase I/II Study of Ixabepilone plus Capecitabine in Anthracycline–Pretreated/Resistant and Taxane-Resistant Metastatic Breast Cancer
Bunnell, Craig, Vahdat, Linda, Schwartzberg, Lee, Gralow, Julie, Klimovsky, Judith, Poulart, Valerie, Peck, Ronald, Thomas, Eva
Published in Clinical breast cancer (01.06.2008)
Published in Clinical breast cancer (01.06.2008)
Get full text
Journal Article
Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET)
Yao, James C., Hainsworth, John D., Wolin, Edward M., Pavel, Marianne E., Baudin, Eric, Gross, David, Ruszniewski, Philippe, Tomassetti, Paola, Panneerselvam, Ashok, Saletan, Stephen, Klimovsky, Judith
Published in Journal of clinical oncology (01.02.2012)
Published in Journal of clinical oncology (01.02.2012)
Get full text
Journal Article
Updated safety results from EXIST-2: Everolimus therapy for angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sLAM)
Bissler, John, Kingswood, Christopher, Zonnenberg, B. A., Frost, Michael, Belousova, Elena, Radzikowska, Elzbieta, Sauter, Matthias, Nonomura, Norio, Brakemeier, Susan, de Vries, Petrus, Klimovsky, Judith, Shah, Gaurav D., Miao, Sara, Lincy, Jeremie, Budde, Klemens
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article